Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase III Pipeline Programs

Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Programs 5,427
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 5,427 phase iii pharmaceutical pipeline programs from ClinicalTrials.gov. Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Top sponsors

Pipeline programs

Page 60 of 114

  1. M16-043

    AbbVie Deutschland GmbH & Co. KG

    Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  2. M16-066

    AbbVie Deutschland GmbH & Co. KG

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  3. M16-194

    AbbVie Deutschland GmbH & Co. KG

    Crohn's disease

    phase 3 small molecule active

    1 trial

  4. M16-852

    AbbVie Deutschland GmbH & Co. KG

    Giant Cell Arteritis

    phase 3 small molecule active

    1 trial

  5. M17-380

    AbbVie Deutschland GmbH & Co. KG

    Dermatitis atopic

    phase 3 small molecule active

    1 trial

  6. M19-063

    AbbVie Deutschland GmbH & Co. KG

    Acute Myeloid Leukaemia

    phase 3 small molecule active

    1 trial

  7. M19-708

    AbbVie Deutschland GmbH & Co. KG

    Acute Myeloid Leukemia in First Remission

    phase 3 small molecule active

    1 trial

  8. M19-751

    AbbVie Deutschland GmbH & Co. KG

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  9. M20-621

    AbbVie Deutschland GmbH & Co. KG

    Diffuse Large B-Cell Lymphoma (DLBCL)

    phase 3 small molecule active

    1 trial

  10. M20-638

    AbbVie Deutschland GmbH & Co. KG

    Relapsed and Refractory Follicular Lymphoma

    phase 3 small molecule active

    1 trial

  11. M22-003

    AbbVie Deutschland GmbH & Co. KG

    Follicular Lymphoma

    phase 3 small molecule active

    1 trial

  12. M22-128

    AbbVie Deutschland GmbH & Co. KG

    Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

    phase 3 small molecule active

    1 trial

  13. M22-574

    AbbVie Deutschland GmbH & Co. KG

    Relapsed or Refractory Multiple Myeloma (RRMM)

    phase 3 small molecule active

    1 trial

  14. M23-716

    AbbVie Deutschland GmbH & Co. KG

    Alopecia Areata

    phase 3 small molecule active

    1 trial

  15. M23-721

    AbbVie Deutschland GmbH & Co. KG

    Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer, Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer, Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer, Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  16. M23-732

    AbbVie Deutschland GmbH & Co. KG

    Juvenile Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  17. M24-052

    AbbVie Deutschland GmbH & Co. KG

    Metastatic Hepatocellular Carcinoma (HCC)

    phase 3 small molecule active

    1 trial

  18. M24-064

    AbbVie Deutschland GmbH & Co. KG

    Metastatic Colorectal Cancer

    phase 3 small molecule active

    1 trial

  19. M24-287

    AbbVie Deutschland GmbH & Co. KG

    Chronic Lymphocytic Leukemia

    phase 3 small molecule active

    1 trial

  20. M25-287

    AbbVie Deutschland GmbH & Co. KG

    Non-Squamous Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  21. M25-540

    AbbVie Deutschland GmbH & Co. KG

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  22. M25-586

    AbbVie Deutschland GmbH & Co. KG

    Multiple Myeloma

    phase 3 small molecule active

    1 trial

  23. M25-713

    AbbVie Deutschland GmbH & Co. KG

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  24. M602011014

    Merz Pharmaceuticals GmbH

    Lower limb spasticity

    phase 3 small molecule active

    1 trial

  25. M602011072

    Merz Pharmaceuticals GmbH

    Pediatric lower limb (LL) spasticity (SP) caused by cerebral palsy (CP)

    phase 3 small molecule active

    1 trial

  26. M602011084

    Merz Therapeutics GmbH

    Chronic migraine

    phase 3 small molecule active

    1 trial

  27. M602011085

    Merz Therapeutics GmbH

    Episodic migraine

    phase 3 small molecule active

    1 trial

  28. MAT2203

    Matinas BioPharma Holdings

    Cryptococcal Meningitis

    phase 3 small molecule active

    2 trials

  29. MB-102 DMID

    Hangzhou Zhongmei Huadong Pharmaceutical Co.,

    Kidney Diseases

    phase 3 small molecule completed

    1 trial

  30. MB-108

    Moleculin Biotech

    Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  31. MB04-C-01-23

    Mabxience Research SL

    Rheumatoid Arthritis

    phase 3 small molecule active

    1 trial

  32. MB11-C-01-25

    Mabxience Research SL

    Previously Untreated Advanced (Unresectable or Metastatic) Melanoma

    phase 3 small molecule active

    1 trial

  33. MB12-C-02-24

    Mabxience Research SL

    advanced/metastatic non-squamous non-small cell lung cancer (NSCLC)

    phase 3 other active

    1 trial

  34. MC-MSC.1/aGvHD

    Medac Gesellschaft fuer klinische Spezialpraeparate mbH

    Steroid refractory Acute Graft versus host Disease

    phase 3 small molecule active

    1 trial

  35. MC-MTX.18/AD

    Medac Gesellschaft fuer klinische Spezialpraeparate mbH

    moderate to severe atopic dermatitis

    phase 3 small molecule active

    1 trial

  36. MCT8-2021-3

    Rare Thyroid Therapeutics International AB

    Monocarboxylate Transporter 8 (MCT8) deficiency

    phase 3 small molecule active

    1 trial

  37. MCV-ACYW135 Vaccine Group

    Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

    Meningitis

    phase 3 mab completed

    1 trial

  38. MDS0519

    Fondazione Telethon ETS

    Higher-risk-myelodysplastic syndromes

    phase 3 small molecule active

    1 trial

  39. MEDI4736

    AstraZeneca

    Non-Small Cell Lung Cancer

    phase 3 small molecule completed

    1 trial

  40. MEDI4736

    AstraZeneca

    Squamous Cell Carcinoma of the Head and Neck

    phase 3 mab completed

    1 trial

  41. MEDI4736 (Durvalumab)

    AstraZeneca

    Non-Small-Cell Lung Carcinoma NSCLC

    phase 3 mab active

    1 trial

  42. MEDI4736 Placebo, DURVALUMAB

    CERO THERAPEUTICS HOLDINGS, INC.

    Completely resected primary stage IB (≥ 4cm), II and IIIA non-small cell lung cancer patients

    phase 3 small molecule active

    1 trial

  43. MEDOPP545

    Stemline Therapeutics B.V.

    patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced breast cancer progressing to endocrine therapy and CDK4/6 inhibitors.

    phase 3 small molecule active

    1 trial

  44. MEP

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Carcinoma

    phase 3 small molecule terminated

    1 trial

  45. MEPOLIZUMAB

    GlaxoSmithKline

    Hypereosinophilic syndrome (HES)

    phase 3 small molecule active

    1 trial

  46. MEQ00073

    Sanofi Pasteur

    Meningococcal infection

    phase 3 small molecule active

    1 trial

  47. MEQ00074

    Sanofi Pasteur

    Meningococcal Infection

    phase 3 mab completed

    1 trial

  48. MEQ00089

    Sanofi Pasteur

    Healthy volunteers (Meningococcal infection)

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many Phase III pipeline programs are in the directory?

5,427 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.